The efficacy of anti-PD-1 agents in acral and mucosal melanoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Brain Neoplasms
  • Liver Neoplasms
  • Melanoma
  • Mucous Membrane
  • Programmed Cell Death 1 Receptor
  • Skin Neoplasms

abstract

  • Response rates to PD-1 blockade in patients with acral and mucosal melanomas were comparable to the published rates in patients with cutaneous melanoma and support the routine use of PD-1 blockade in clinical practice. Further investigation is needed to identify the mechanisms of response and resistance to therapy in these subtypes. Cancer 2016;122:3354-3362. © 2016 American Cancer Society.

publication date

  • November 15, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5134420

Digital Object Identifier (DOI)

  • 10.1002/cncr.30259

PubMed ID

  • 27533633

Additional Document Info

start page

  • 3354

end page

  • 3362

volume

  • 122

number

  • 21